Artur Isaev
Founder and CEO of Human Stem Cell Institute OJSC (HSCI, www.eng.hsci.ru; MOEX: ISKJ).
Founder of Gemabank – the largest private cord blood stem cell bank in Russia.
Founder and publisher of the scientific and analytical journal Genes & Cells (before 2014 known as "Cell
Transplantology and Tissue Engineering").
Member of the Board of Directors of Xenetic Biosciences Inc, a biopharmaceutical company (MA, USA;
OTC/BB: XBIO).
Winner of the Entrepreneur of the Year 2012 Award in hi-tech in Russia conducted by Ernst & Young.
Artur Isaev holds MD from Rostov State Medical University (1994) and MBA from Moscow International
Business School MIRBIS (1998).
From 1994 to 1999 Artur Isaev headed an investment-brokerage company, from 1999 to 2003 he was a CEO of
Mauer-Audit & Partners auditing and consulting group. Among other things, he was a co-investor in SMI-link
project on the base of which Yandex.Traffic Jams internet service was created in Russia.
In 2003 Artur Isaev founded Human Stem Cells Institute – a Russian biotech company, and in 2004 HSCI
opened Gemabank – one of Russia’s first cord blood banks.
HSCI became the first Russian biotech to go public – in 2009 Artur Isaev conducted HSCI's IPO on the MICEX
– now MOEX (Moscow Exchange), and then turned HSCI into multifaceted biotech company with a wide range
of products and services.
As of today, HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and
services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive
genetics, gene therapy and biopharmaceutics.
Under Mr. Isaev’s leadership, in 2011 HSCI obtained marketing authorization and in 2012 launched in Russia
Neovasculgen®, the first-in-class gene-therapy drug for the treatment of Peripheral Arterial Disease (PAD),
including Critical Limb Ischemia (CLI). The drug’s action mechanism – therapeutic angiogenesis – introduces
a new approach to treating ischemia.
In 2011 HSCI also brought to the market SPRS-therapy – the innovative cell technology which entails the use
of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
In 2011 HSCI initiated and became a co-investor in SynBio – a long-term multilateral project to create new
unique medicines (first-in-class and BioBetters). The SynBio project unites Russian and international biopharm
companies, including Pharmsynthez and Xenetic Biosciences, and is supported by an investment from
RUSNANO (a Russian state-owned fund for supporting nanotechnologies).
In 2013 HSCI launched Reprobank – a reproductive cell and tissue bank (personal storage, donation).
Currently, HSCI is implementing a socially significant project to create its own Russia-wide network of
Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the
aim
of
early
identification,
prediction
and
prophylactic
treatment
of
genetic
disorders (incl. PGD and NIPT among others). Starting 2013, DNA testing services have been provided using
the facilities of HSCI’s new laboratory and production complex opened in Moscow.
As a part of its activities to support innovations, Artur Isaev is a co-founder of IPOboard – an online
information and trading system that helps promising non-public innovative companies raise capital. The project
is a part of Innovation & Investment Market (iIM) of the Moscow Exchange.
In 2014 HSCI, supported by Moscow City Government, held the first international investment conference
Moscow Life Sciences Investment Day-2014.
In 2014 HSCI also won the biggest in Russian history lawsuit protecting the reputation of cell technology and
cord blood banks.